RxDoctor Payments Data

Mario Pineiro, MD

Internal Medicine · Henderson, NVNPI 1306807425

Payments from drug & device makers

$895in general payments, 2019–2025

Across 34 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$261
  • Johnson & Johnson$220
  • AbbVie$154
  • Lilly USA, LLC$118
  • Pfizer$53
  • AstraZeneca$30
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$895 in reported general payments places this provider in the 70th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$90,471
Medicare patients
127
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate102$81,775
EliquisApixaban59$46,123
XareltoRivaroxaban41$43,904
VascepaIcosapent Ethyl102$37,516
JardianceEmpagliflozin33$37,102
Janumet XrSitagliptin Phos/Metformin Hcl24$23,419
OzempicSemaglutide24$21,021
TradjentaLinagliptin24$19,787
LinzessLinaclotide20$16,630
MovantikNaloxegol Oxalate15$12,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,791
Diclofenac Sodium106$5,393
Albuterol Sulfate HfaAlbuterol Sulfate168$5,031
Ventolin HfaAlbuterol Sulfate71$3,733
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$18$105,193126 claims
PfizerEliquis$53$46,12359 claims
Johnson & JohnsonXarelto$220$43,90441 claims
AbbVieLinzess$154$16,63020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →